Related Experiment Video

Updated: Dec 31, 2025

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
09:03

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula

Published on: January 26, 2024

618

Antineoplastic effects of sorafenib on primary liver cancer: a systematic review and meta-analysis

Meizhen Liu1, Rui Zhou2, Xiaoliu Liang1

  • 1College of Pharmacy, Guangxi Medical University Nanning 530021, Guangxi, PR China.

International Journal of Clinical and Experimental Pathology
|January 15, 2020
PubMed
Abstract

Insights

Sorafenib demonstrates significant therapeutic efficacy in treating primary liver cancer (PLC). While treatment duration has a limited impact, sorafenib effectively improves patient survival rates.

Area of Science:

  • Oncology
  • Hepatology
  • Clinical Pharmacology

Background:

  • Primary liver cancer (PLC) presents a significant global health challenge.
  • Effective therapeutic strategies for PLC are continuously sought.
  • Sorafenib is an established targeted therapy for advanced liver cancer.

Purpose of the Study:

  • To evaluate the therapeutic efficacy of sorafenib in patients with primary liver cancer (PLC).
  • To analyze the impact of treatment duration on sorafenib's efficacy in PLC.
  • To assess sorafenib's effect on survival rates in PLC patients.

Main Methods:

  • A systematic review and meta-analysis of randomized controlled trials (RCTs).
  • Searched PubMed, CNKI, WanFang, and Civip databases for relevant studies from November 2006 to May 2018.
  • Included 15 RCTs involving 1102 patients with primary liver cancer.

Main Results:

  • Sorafenib demonstrated significant overall clinical efficacy compared to controls (OR, 3.38; 95% CI, 2.57-4.46; P < 0.05).
  • Efficacy was consistent across subgroups regardless of treatment duration.
  • Treatment duration exceeding 100 days showed higher efficacy than control groups (OR, 4.61; 95% CI, 2.58-8.29; P < 0.05).

Conclusions:

  • Sorafenib is clinically effective for treating primary liver cancer.
  • Treatment duration has a limited impact on sorafenib's therapeutic efficacy in PLC.
  • Sorafenib can extend survival rates in patients diagnosed with primary liver cancer.
Keywords:
Sorafenibmeta-analysissurvival ratetherapeutic efficacy

More Related Videos

The Influence of Liver Resection on Intrahepatic Tumor Growth07:55

The Influence of Liver Resection on Intrahepatic Tumor Growth

Published on: April 9, 2016

9.8K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

992

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
137
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
172
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
205
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
161